 CAMBRIDGE, Mass., March 10, 2021 GLOBE NEWSWIRE -- TCR2 Therapeutics Inc. Nasdaq: TCRR, a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that three e-poster presentations featuring new clinical data from the ongoing Phase 1 portion of the gavo-cel Phase 12 clinical trial for treatment refractory mesothelin-expressing solid tumors and preclinical data on its pipeline programs will be presented at the American Association for Cancer Research AACR Virtual Annual Meeting, taking place April 10-15, 2021. 